Patera News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patera. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patera Today - Breaking & Trending Today

Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc

Natera Inc (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, has seen a recent insider transaction according to the latest SEC Filing. ....

Natera Inc , Michael Brophy , Nsider Transaction , Nsider Transactions ,

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

AUSTIN, Texas, April 11, 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here. ....

United States , San Carlos , Jonathan Bromberg , Samaniego Picota Milagros , Sangeeta Bhorade , Natera Inc , Clinical Laboratory Improvement Amendments , University Of Maryland School Medicine , Drug Administration , Prospera Kidney , Maryland School , Kidney Transplant Injury , Donor Derived Cell Free , Massively Multiplex , Detect Kidney Allograft , Biopsy Proven Rejection , Kidney Transplant , Acute Rejection , Prospera Kidney ,

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

AUSTIN, Texas, April 05, 2024 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test. ....

United States , France General , San Carlos , John Simmons , Drug Administration , Clinical Laboratory Improvement Amendments , Roche Group , Natera Inc , European Association Of Urology , European Association , Professor Powles , Bladder Cancer , Global Leader , Phase Iii Trial ,

Is Natera (NTRA) On The Cusp Of Being Cash Flow Positive?

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds released “The RiverPark/Next Century Growth Fund” Q4 2023 investor letter in partnership with Next Century Growth Investors, LLC. A copy of the same can be downloaded here. The fund returned 4.75% in the fourth quarter compared to a 12.75% return […] ....

Natera Inc , Popular Stocks Among Hedge , Next Century Growth Investors , Growth Fund , Nvestor Letter , Fourth Quarter ,

Natera (NTRA) Management Increased Full Year Guidance

Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. US markets rallied strongly in Q4, with the S&P Index up 11.69%. However, Class A shares of the fund underperformed the Russell 2500 Growth Index. Healthcare and IT […] ....

Natera Inc , Popular Stocks Among Hedge , Alger Weatherbie Specialized Growth Fund , Fred Alger Management , Investment Management Company , Fourth Quarter , Nvestor Letter ,